RMD FY26 result-- FY27 looks challenging but should be manageable
RMD FY26 My Thoughts The result was in line with my estimates, with revenues in line and NPAT 1% below. The result was strong, with 8% cc revenue growth and 290bp GM expansion, together with share buybacks resulting in 16% non-GAAP eps growth. There was a noticeable change in tone and narrative in Q4 commentary. RMD has become a bit more cautious and defensive compared to the confidence displayed in the first three quarters. That leads to the question: why? The exit rates do not look as good as the extrapolating full-year momentum implies. There were also some negatives in Q4, which should be looked at. The extent of the ventilator field action was disclosed as a $42m charge to repair infield ventilators and a $75m revenue headwind, as sales will cease until the full extent of the damage is known, at least a year. The management described the provisions as conservative. Although it appears very few devices are impaired, every one of them will have to be checked, is my rea...